Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis

المؤلف

Yusuf, Dua Muhammad

المصدر

Saudi Journal of Kidney Diseases and Transplantation

العدد

المجلد 23، العدد 4 (31 أغسطس/آب 2012)، ص ص. 755-764، 10ص.

الناشر

المركز السعودي لزراعة الأعضاء

تاريخ النشر

2012-08-31

دولة النشر

السعودية

عدد الصفحات

10

التخصصات الرئيسية

الطب البشري

الموضوعات

الملخص EN

Children with chronic kidney disease are at high risk for growth retardation and decreased adult height.

Growth hormone (GH) treatment is known to stimulate growth in children with short stature suffering from chronic kidney disease.

However, the extent to which this therapy affects final adult height is not known.

This study was performed on 15 patients with end stage renal disease (ESRD) on regular hemodialysis to detect the effect of using recombinant human growth hormone (rhGH) on growth of patients with ESRD on regular hemodialysis and comparing this effect with the growth velocity in the same group without using rhGH in the year before therapy.

There were eight females and seven males with mean age 10.6 ± 2.8 (range 5–14 years).

For each patient, recombinant GH was given for one year, three-times weekly.

The data of these 15 patients was compared with the year before treatment versus data of the same group of patients after six months and after one year of rhGH therapy.

Our results showed that, in the year before therapy, height of these patients increased from a mean of 112.1 ± 11.6 cm to 112.7 ± 11.5 cm, which is a non-significant increase statistically (P > 0.05) as well as clinically (mean growth velocity 0.6 cm / year), while height of these patients increased from a mean of 112.7 ± 11.5 cm at the start of therapy to 116.8 ± 11 cm after therapy for one year, which, although statically not significant (P < 0.05), was of clinical significance as it makes rate of increase, i.e.

the mean growth velocity, 4.1 cm / year close to the normal growth velocity, which is 5 cm/year, before puberty.

RhGH therapy for patients with ESRD on regular hemodialysis is helpful in height gain and catch-up growth even when given three-times per week instead of five- or six-times per week.

We recommend giving rhGH therapy as a routine supplementation to pediatric patients before epiphyseal closure.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Yusuf, Dua Muhammad. 2012. Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis. Saudi Journal of Kidney Diseases and Transplantation،Vol. 23, no. 4, pp.755-764.
https://search.emarefa.net/detail/BIM-312215

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Yusuf, Dua Muhammad. Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis. Saudi Journal of Kidney Diseases and Transplantation Vol. 23, no. 4 (Aug. 2012), pp.755-764.
https://search.emarefa.net/detail/BIM-312215

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Yusuf, Dua Muhammad. Results of recombinant growth hormone treatment in children with end-stage renal disease on regular hemodialysis. Saudi Journal of Kidney Diseases and Transplantation. 2012. Vol. 23, no. 4, pp.755-764.
https://search.emarefa.net/detail/BIM-312215

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

38

رقم السجل

BIM-312215